Semaglutide (2.4 mg) significantly improved symptoms, physical limitations, exercise function, and caused greater weight loss compared to placebo in heart failure patients with preserved ejection frac
Does semaglutide (2.4 mg) improve symptoms, physical limitations, exercise function, and weight loss in patients with heart failure with preserved ejection fraction and obesity?
In patients with HFpEF and obesity, semaglutide 2.4 mg significantly improves heart failure symptoms, physical limitations, and exercise function while promoting weight loss.
Tasa de eventos absoluta: 0% vs 0%
In patients with heart failure with preserved ejection fraction and obesity, treatment with semaglutide (2.4 mg) led to larger reductions in symptoms and physical limitations, greater improvements in exercise function, and greater weight loss than placebo. (Funded by Novo Nordisk; STEP-HFpEF ClinicalTrials.gov number, NCT04788511.).
Kosiborod et al. (Fri,) reported a other. Semaglutide (2.4 mg) significantly improved symptoms, physical limitations, exercise function, and caused greater weight loss compared to placebo in heart failure patients with preserved ejection frac.